## Adjuvant Chemotherapy in Poor-Response Osteosarcoma **Key Point:** Patients with poor histological response to neoadjuvant chemotherapy (<90% tumor necrosis) have significantly worse prognosis and require intensified adjuvant therapy. The addition of ifosfamide to the standard cisplatin-doxorubicin backbone is the evidence-based approach to improve survival in this high-risk group. ### Stratification by Necrosis | Tumor Necrosis | Prognosis | Adjuvant Regimen | |---|---|---| | >90% (good response) | 5-yr survival ~80% | Cisplatin + doxorubicin (standard) | | <90% (poor response) | 5-yr survival ~50% | Cisplatin + doxorubicin + ifosfamide (intensified) | **High-Yield:** The degree of necrosis is the single most important prognostic factor in osteosarcoma. Poor responders require dose-escalation or addition of third agents (ifosfamide) to improve cure rates. ### Ifosfamide's Role in Poor Responders - **Mechanism:** Alkylating agent; structurally related to cyclophosphamide but with different spectrum of activity. - **Timing:** Added to cisplatin-doxorubicin in adjuvant phase for poor responders. - **Efficacy:** Randomized trials (e.g., EURAMOS-1) demonstrated improved event-free survival when ifosfamide was added to standard therapy in poor responders. - **Toxicity:** Hemorrhagic cystitis (requires aggressive hydration and mesna), neurotoxicity, myelosuppression. **Clinical Pearl:** The EURAMOS-1 trial (2018) was a landmark study showing that adding ifosfamide to cisplatin-doxorubicin in poor responders improved 5-year event-free survival from ~50% to ~65%, making this the new standard for this subgroup. **Warning:** Ifosfamide requires mesna (uroprotective agent) and aggressive IV hydration to prevent hemorrhagic cystitis. Baseline and serial renal function monitoring is essential. [cite:Robbins 10e Ch 26]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.